Argenx

Argenx SE is a commercial-stage Dutch biopharmaceutical company headquartered in Amsterdam, Netherlands, that specializes in developing antibody-based therapies for severe autoimmune diseases. Founded on the proprietary SIMPLE Antibody platform, the company achieved a major commercial breakthrough with its flagship drug, Vyvgart (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) blocker targeting conditions such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). Objectively, Argenx has transitioned into a highly profitable market leader, generating $4.15 billion in product net sales in 2025. However, its business model carries significant concentrated risk, as over 95% of its top-line revenue depends entirely on the single molecular entity efgartigimod across various delivery forms and indications. Additionally, the company faces rising commercial and R&D overhead—totaling over $2.7 billion in 2025—alongside intensifying competition from alternative FcRn inhibitors (such as Johnson & Johnson’s nipocalimab and UCB’s Rystiggo) and pipeline trial setbacks, such as its failed Phase 2a trial in ALS.

History and business model

Market position and competitiors

Below is a list of articles for the company:

  • Argenx: 2026Q2 Earnings

    Financial Highlights Argenx reported total revenue of $917.4 million for Q2 2026, marking a 95% increase compared to $470.2 million in Q2 2025. Net income reached $182.3 million ($2.95 per diluted share), representing a major turnaround from a net loss of $29.8 million in the prior-year period. The financial performance was primarily driven by the…

  • Argenx: supply chain and competitions

    Market Position and Market Share Argenx SE (NASDAQ: ARGX) is a global leader in the development of therapies for severe autoimmune diseases, operating primarily as a pioneer in the neonatal Fc receptor (FcRn) blocker class. Supply Chain Analysis and Key Suppliers Argenx operates under a “fabless” biopharmaceutical model, outsourcing manufacturing, delivery technologies, and clinical development…

  • Argenx: history and business model

    Company History Foundational Stage (2008–2013) Argenx was founded in 2008 in Ghent, Belgium, by Tim Van Hauwermeiren, Hans de Haard, and Torsten Dreier. The company initially operated as an early-stage biotechnology research firm focused on novel antibody engineering. During this phase, it developed its core technology platforms, including the SIMPLE Antibody discovery platform (leveraging the…